- About
- IgAN
- Events
- Resource Center
- Simulators
What interests you?+Help Us Enhance Your NephU ExperienceHelp Us Enhance Your NephU Experience
User experience form
Archives
Role of the Renal Pathologist in IgA Nephropathy
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Role of the Renal Pathologist in IgA Nephropathy
Background
IgA Nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and is a leading cause of chronic kidney disease1. Characterized by the deposition of IgA antibodies in the glomeruli2, the clinical manifestations of IgAN vary from asymptomatic with microscopic or intermittent macroscopic hematuria and stable kidney function to rapidly progressive glomerulonephritis3. The variability in disease progression underscores the importance of renal pathology in the diagnosis and risk stratification of patients with IgAN.Did You Know?
- The diagnosis of IgAN requires a kidney biopsy showing dominant or co-dominant mesangial IgA staining3.
- The prevalence of IgAN varies, as IgAN accounts for almost 40% of biopsy-confirmed glomerular disease in Asian countries compared with ~10% in the United States and ~20% in Europe4.
- Over a period of 20–30 years, as many as 30–40% of adult patients with IgAN progress to kidney failure3.
Why Watch this Webinar?
- Through the lens of renal pathology, this webinar will provide insights into the histopathological features that are crucial for accurate diagnosis and risk stratification in IgA Nephropathy, highlighting the significance of the renal biopsy and its interpretation.
What You Will Learn
- Introduction to IgA Nephropathy: Brief overview of IgAN, including pathophysiology and clinical features.
- Role of the renal pathologist: An overview of the role of renal pathology in IgAN, diagnostic strategies, and other critical pathology insights.
- Histopathological hallmarks: Key features in renal biopsies, including an overview of the MEST-C scoring system and its prognostic value in assessing disease severity.
References:
- Gutiérrez E, et al. Nephrol Dial Transplant. 2018;33(3):472-477.
- Yu HH, Chiang BL. Autoimmun Rev. 2014;13(4-5):556-559.
- Stamellou E, et al. Nat Rev Dis Primers. 2023;9(67).
- O’Shaughnessy MM, et al. Nephrol Dial Transplant. 2018;33(4):661-669.
Speaker
Jared Hassler, MD
Pathologist and Associate Professor of Pathology and Laboratory Medicine at the Lewis Katz School of Medicine at Temple UniversityDr. Jared Hassler is a pathologist at Temple University Hospital and Associate Professor of Pathology and Laboratory Medicine at the Lewis Katz School of MedicineTemple University. Dr Hassler was diagnosed with IgA Nephropathy in 2001; his diagnosis cemented his decision to pursue a career in medicine. After his kidneys failed during his third year of medical school, he was started on hemodialysis and then peritoneal dialysis. He completed his medical degree at University of Tennessee’s School of Medicine in 2012 after his wife donated one of her kidneys. He then went on to complete his pathology residency and renal and transplant fellowship at University of Texas Southwestern Medical Center in Dallas, Texas. Dr Hassler’s clinical and research interests include IgA Nephropathy, solid organ transplantation and transplant rejection, and BK virus nephropathy.
Moderator
Josh Gariboldi, PharmD, BCPS
Nephrology Senior Medical Science LiaisonOtsuka Pharmaceutical Development & Commercialization, Inc.*
Josh Gariboldi, PharmD, BCPS joined Otsuka in January 2021 and is a Senior Medical Science Liaison on our Nephrology East Team, covering the Carolinas and Tennessee. Dr Gariboldi earned his Doctor of Pharmacy degree from the University of Florida in 2012. He has more than eight years of experience as a clinical pharmacist in both the community and hospital settings, most recently at Bon Secours Mercy Health St. Francis Hospital in Greenville, SC. Dr Gariboldi served as a preceptor with Presbyterian College School of Pharmacy, where he instructed students on Advanced Pharmacy Practice rotations. He holds board certifications in both pharmacotherapy and medical affairs.
Dr. Jared Hassler is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.
Dr. Josh Gariboldi is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.
Disclaimer: The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional.
August 2024 US.CORP.X.24.00249Registration
Related Events
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2024 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved. - IgAN
